GET DAILY SIGNALSVivoSim Labs (VIVS) Earnings Preview: Key Details Ahead of Fiscal Q2 2027 Results
Key Takeaways
- VivoSim Labs is expected to report results for its fiscal second quarter of 2027 (the three months ended September 30, 2026) in early-to-mid November 2026.
- The company operates in a niche segment of preclinical testing, using 3D human tissue models for liver and intestine toxicity screening.
- Formal analyst consensus estimates are extremely limited, so investors will likely focus on cash burn, revenue traction, and the adoption of its New Approach Methodologies (NAM, or non-animal testing methods).
- Recent capital raises, including a $4.0 million private placement in July 2026, underscore the company's near-term focus on liquidity and working capital.
- The stock trades at a market capitalization near $2.4 million, with limited institutional ownership and elevated volatility.
- For additional context on VivoSim Labs, you can explore its Major News, Today's Price Move, Price Targets, and Forecast pages.
- Investors looking for AI-driven trade ideas can also explore Trending AI Robots.
Understanding the Earnings Context
VIVS is a pharmaceutical and biotechnology services company that develops three-dimensional human tissue models used to test drugs and drug candidates for liver and intestinal toxicity. The company, formerly known as Organovo Holdings, rebranded in April 2025 and has since been working to reposition itself around New Approach Methodologies (NAM), which offer an alternative to traditional animal-based testing. For a company of this size, quarterly earnings are less about headline profitability and more about execution: whether revenue from its testing services is gaining traction, how quickly cash is being consumed, and whether recent financings provide enough runway to advance its technology. These factors make the upcoming report a key checkpoint for investors gauging the company's path toward commercial sustainability.
What the Numbers Are Likely to Show
Because VIVS carries minimal sell-side coverage, there is no widely published consensus revenue or earnings-per-share estimate for the upcoming quarter. As a result, investors are likely to evaluate the report against the company's own historical trajectory rather than against formal analyst targets. In its fiscal first quarter of 2027, ended June 30, 2026, the company reported a net loss of roughly $1.3 million, or approximately $0.25 per share. For the full fiscal year 2026, which ended March 31, 2026, revenue was approximately $131,000 and the net loss was about $13.8 million. With trailing twelve-month revenue near $112,000, the market will be watching whether service-based revenue is expanding, how operating expenses are trending, and how much cash remains on the balance sheet following recent capital raises. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Market Sentiment and Recent Performance
Sentiment heading into this report remains cautious. VIVS shares have fallen sharply over the trailing twelve months and trade near the lower end of their 52-week range, with a market capitalization of roughly $2.4 million and limited institutional participation. The stock has also seen meaningful dilution, as the company completed a 1-for-12 reverse split in March 2025 and has since pursued multiple financing transactions to support working capital. These dynamics leave the equity sensitive to both the substance of the results and any updates on cash runway, partnerships, or the commercial adoption of its NAM-based testing services. For a thinly traded micro-cap stock, investors should also weigh the risk of outsized price moves around the release.
Looking Ahead: Factors Worth Monitoring
Looking past the quarterly figures, investors will likely focus on several forward-looking signals. First is the company's cash position and how long existing resources can fund operations, given that VIVS remains pre-profit and has relied on recurring financings. Management's commentary on liquidity needs and any plans for additional capital will be closely watched.
Second is revenue visibility. The company generates revenue from liver toxicology screening and research services, but the commercial pipeline remains small. Any indication of new customer engagements, repeat business, or expanded service offerings could be meaningful for the growth narrative.
Third, the broader push toward New Approach Methodologies (NAM) as alternatives to animal testing is a relevant industry tailwind. Progress on regulatory acceptance and adoption of NAM-based models could shape the long-term opportunity, even if near-term financial results remain modest.
Finally, investors should monitor operating expense trends and any updates on strategic initiatives, partnerships, or technology development milestones. For a micro-cap company with limited analyst coverage, clarity on these operational and balance-sheet factors may matter more than the headline loss figure itself.
AI Tools in My Research Process
When analyzing small-cap names like this, I often rely on Tickeron’s AI Screener to quickly filter for comparable companies by market cap, sector trends, and technical signals. It helps surface context on volatility and performance that might otherwise take hours to compile manually, giving a clearer view of where VIVS stands relative to peers.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
VIVS's Stochastic Oscillator remains in oversold zone for 1 day
Be on the lookout for a price bounce soon.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where VIVS's RSI Indicator exited the oversold zone, 35 of 44 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
Following a +12.38% 3-day Advance, the price is estimated to grow further. Considering data from situations where VIVS advanced for three days, in 159 of 205 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VIVS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for VIVS entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 30 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-0.808) is normal, around the industry mean (2.904). P/E Ratio (-0.032) is within average values for comparable stocks, (-0.738). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.314) among similar stocks. P/S Ratio (7.446) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 94 (best 1 - 100 worst), indicating slightly worse than average price growth. VIVS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VIVS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company which engages in developing and commercializing functional human tissues
Industry Biotechnology
Advertisement